Form4insider filings, from the source

SEC Form 4 · accession 0001493152-18-005444

Adhera Therapeutics, Inc. · ATRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Vuong Trieu
Officer — Executive Chairman · Director · 10% Owner
Period of report
Apr 16, 2018
Accepted (ET)
Apr 18, 2018 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000737207

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series E Convertible Preferred StockF2$0.50Apr 16, 2018A2AApr 16, 2018—Common Stock22,5002D
Warrants to Purchase Common StockF3$0.55Apr 16, 2018A16,875AApr 16, 2018—Common Stock16,87516,875D
Series E Convertible Preferred StockF2$0.50Apr 16, 2018C35AApr 16, 2018—Common Stock345,10035D
Warrants to Purchase Common StockF3$0.55Apr 16, 2018C258,825AApr 16, 2018—Common Stock258,825258,825D
5% Convertible Promissory NoteF5,F6$5,000.00Apr 16, 2018C—DApr 16, 2018—Preferred Stock / Warrants——D
Series E Convertible Preferred StockF2$0.50Apr 16, 2018C115AApr 16, 2018—Common Stock1,146,300115D
Warrants to Purchase Common StockF3$0.55Apr 16, 2018C859,725AApr 16, 2018—Common Stock859,725859,725D
5% Demand Line of CreditF5,F8$5,000.00Apr 16, 2018C—DNov 15, 2016—Preferred Stock / Warrants——D
Series E Convertible Preferred StockF10,F2$0.50Apr 16, 2018C19AApr 16, 2018—Common Stock190,00019I
Warrants to Purchase Common StockF10,F3$0.55Apr 16, 2018C142,500AApr 16, 2018—Common Stock142,500142,500I
5% Demand Line of CreditF10,F5,F11$5,000.00Apr 16, 2018C—DApr 16, 2018—Preferred Stock / Warrants——I
Series E Convertible Preferred StockF10,F2$0.50Apr 16, 2018P163AApr 16, 2018—Common Stock1,625,900163I
Warrants to Purchase Common StockF10,F3$0.55Apr 16, 2018P2,564,465AApr 16, 2018—Common Stock2,564,4652,564,465I

Explanation of responses